Background The introduction of non-vitamin K antagonist oral anticoagulants (NOACs) has
been a major advance for stroke prevention in atrial fibrillation (AF). Patients and clinicians …

Background The introduction of non–vitamin K antagonist oral anticoagulants has been a
major advance for stroke prevention in atrial fibrillation; however, outcomes achieved in …

Background Comparative data of non‐vitamin K antagonist oral anticoagulants (NOAC) are
lacking in patients with atrial fibrillation (AF). Objective We compared effectiveness and …

New oral anticoagulant drugs are emerging as alternatives to warfarin for the prevention of
stroke in patients with non-valvular atrial fibrillation. Two agents are direct factor Xa …

Background Effectiveness data on novel oral anticoagulants (NOACs) versus warfarin for
stroke prevention in non-valvular atrial fibrillation (NVAF) by prior warfarin use are limited …

Background Stroke is the most serious clinical consequence of atrial fibrillation, which is the
most common cardiac arrhythmia. Non-vitamin K antagonist oral anticoagulants (NOACs) …

Background and Purpose—Limited real-world data exist comparing each non–vitamin K
antagonist oral anticoagulant (NOAC) to warfarin in patients with nonvalvular atrial …

The non-vitamin K antagonist oral anticoagulants (NOACs) have been increasingly
prescribed in clinical practice for stroke prevention in patients with nonvalvular atrial …

Aims The aim of this study was to compare the risk of stroke or systemic embolism (SE) and
major bleeding in patients with atrial fibrillation (AF) using dabigatran, rivaroxaban, and …

Background and Purpose—This ARISTOPHANES study (Anticoagulants for Reduction in
Stroke: Observational Pooled Analysis on Health Outcomes and Experience of Patients) …